Lindbrook Capital LLC Buys 227 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Lindbrook Capital LLC boosted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 120.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 415 shares of the medical research company’s stock after acquiring an additional 227 shares during the period. Lindbrook Capital LLC’s holdings in Quest Diagnostics were worth $57,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. NBC Securities Inc. bought a new position in Quest Diagnostics during the 3rd quarter worth $25,000. BKM Wealth Management LLC bought a new position in Quest Diagnostics during the 4th quarter worth $29,000. VisionPoint Advisory Group LLC increased its stake in Quest Diagnostics by 100.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after acquiring an additional 109 shares during the period. FinTrust Capital Advisors LLC increased its stake in Quest Diagnostics by 1,100.0% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 264 shares of the medical research company’s stock worth $32,000 after acquiring an additional 242 shares during the period. Finally, Headinvest LLC bought a new position in Quest Diagnostics during the 3rd quarter worth $36,000. Institutional investors own 88.06% of the company’s stock.

Wall Street Analysts Forecast Growth

DGX has been the topic of several recent analyst reports. Jefferies Financial Group upgraded Quest Diagnostics from a “hold” rating to a “buy” rating and lifted their price target for the company from $140.00 to $155.00 in a research note on Wednesday, February 7th. SVB Leerink initiated coverage on Quest Diagnostics in a research note on Monday, February 26th. They issued a “market perform” rating and a $135.00 price target on the stock. Mizuho lifted their price target on Quest Diagnostics from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup lifted their price target on Quest Diagnostics from $135.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Truist Financial lifted their price target on Quest Diagnostics from $145.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Quest Diagnostics has a consensus rating of “Hold” and an average target price of $146.17.

Quest Diagnostics Trading Down 1.5 %

Shares of DGX stock opened at $135.47 on Friday. The firm has a market capitalization of $15.04 billion, a P/E ratio of 18.09, a P/E/G ratio of 2.95 and a beta of 0.91. Quest Diagnostics Incorporated has a twelve month low of $119.59 and a twelve month high of $147.96. The company has a quick ratio of 1.20, a current ratio of 0.97 and a debt-to-equity ratio of 0.59. The stock’s fifty day simple moving average is $128.89 and its 200 day simple moving average is $131.11.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, April 23rd. The medical research company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.86 by $0.18. The firm had revenue of $2.37 billion for the quarter, compared to the consensus estimate of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The business’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.04 EPS. As a group, sell-side analysts predict that Quest Diagnostics Incorporated will post 8.75 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 22nd. Shareholders of record on Monday, April 8th were issued a dividend of $0.75 per share. The ex-dividend date of this dividend was Friday, April 5th. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.71. This represents a $3.00 annualized dividend and a yield of 2.21%. Quest Diagnostics’s payout ratio is presently 37.92%.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 5,611 shares of Quest Diagnostics stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $125.88, for a total transaction of $706,312.68. Following the transaction, the senior vice president now directly owns 38,478 shares of the company’s stock, valued at approximately $4,843,610.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 5,611 shares of Quest Diagnostics stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $125.88, for a total transaction of $706,312.68. Following the transaction, the senior vice president now directly owns 38,478 shares of the company’s stock, valued at approximately $4,843,610.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael E. Prevoznik sold 661 shares of Quest Diagnostics stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $126.14, for a total value of $83,378.54. Following the transaction, the senior vice president now directly owns 40,206 shares in the company, valued at $5,071,584.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,150 shares of company stock valued at $1,913,202. 0.79% of the stock is currently owned by company insiders.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.